Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment.
about
Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics.Measuring adverse events in psychiatry.Serotonin 5-HT(2A) Receptor Function as a Contributing Factor to Both Neuropsychiatric and Cardiovascular Diseases.Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder.Influence of Acute Antipsychotic Treatment on Cardiorespiratory Coupling and Heart Rate Variability.
P2860
Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Assessing cardiovascular risks ...... antipsychotic drug treatment.
@ast
Assessing cardiovascular risks ...... antipsychotic drug treatment.
@en
Assessing cardiovascular risks ...... antipsychotic drug treatment.
@nl
type
label
Assessing cardiovascular risks ...... antipsychotic drug treatment.
@ast
Assessing cardiovascular risks ...... antipsychotic drug treatment.
@en
Assessing cardiovascular risks ...... antipsychotic drug treatment.
@nl
prefLabel
Assessing cardiovascular risks ...... antipsychotic drug treatment.
@ast
Assessing cardiovascular risks ...... antipsychotic drug treatment.
@en
Assessing cardiovascular risks ...... antipsychotic drug treatment.
@nl
P2093
P1476
Assessing cardiovascular risks ...... l antipsychotic drug treatment
@en
P2093
Alexander H Glassman
Herbert Y Meltzer
Michael Davidson
W Victor R Vieweg
P478
63 Suppl 9
P577
2002-01-01T00:00:00Z